Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 15/20 | 0.41 |
| ▸ | NOS3 | P29474 | 12/20 | 0.41 |
| ▸ | NOS2 | P35228 | 9/20 | 0.41 |
| ▸ | DCK | P27707 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584378 | 0.95 | NOS1 (0.44) | NOS1NOS3NOS2 | |
| SCHEMBL422892 | 0.85 | NOS1 (0.36) | NOS1NOS3NOS2 | |
| SCHEMBL4282766 | 0.85 | NOS1 (0.53) | NOS1NOS3NOS2DCK | |
| SCHEMBL6583088 | 0.80 | NOS1 (0.40) | NOS1NOS3NOS2 | |
| SCHEMBL221914 | 0.80 | NOS3 (0.63) | NOS1NOS3NOS2 | |
| SCHEMBL221387 | 0.76 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| SCHEMBL6583956 | 0.76 | NOS1 (0.48) | NOS1NOS3NOS2DCK | |
| SCHEMBL4284903 | 0.76 | NOS1 (0.54) | NOS1NOS3NOS2DCK | |
| SCHEMBL4291359 | 0.73 | NCF1 (0.53) | NOS1NOS3NOS2 | |
| SCHEMBL221742 | 0.73 | NOS1 (0.51) | NOS1NOS3NOS2DCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRTRIS PHARMACEUTICAS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20070248590-A1 | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRT1, SIRT5, SIRT2 | NOS1 728/4885NOS3 1835/4885NOS2 1029/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | NOS1 1659/4885NOS3 1327/4885NOS2 1778/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | NOS1 1659/4885NOS3 1327/4885NOS2 1778/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NOS1 357/4885NOS3 349/4885NOS2 422/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NOS1 357/4885NOS3 349/4885NOS2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.